Win ratio analysis of the LANDMARK trial
Loading...
Contact
Check for full-text access
Issue Date
Type
Article
Language
Keywords
Alternative Title
Abstract
The LANDMARK trial reported the non-inferiority of the Myval transcatheter heart valve (THV) series compared with the contemporary standard THV series (Sapien and Evolut) for a 30-day composite endpoint in patients with severe aortic stenosis. This exploratory study compared the performance of the Myval THV series with the contemporary THV series using the win ratio analysis. Copyright © 2025 The Author(s)
Description
Citation
Publisher
License
Journal
American Heart Journal
Volume
289